Osteoarthritis year 2011 in review: biochemical markers of osteoarthritis: an overview of research and initiatives.

[en] The "year in review" session is a key moment of the Osteoarthritis Research Society International (OARSI) Congress. This is a unique opportunity for opinion leaders to summarize and comment the recent advances in one particular field of osteoarthritis research. This review is a summary of selected studies related to soluble biomarkers published between September 1st, 2010 and August 30th, 2011 and identified by a pubmed search using the terms "biomarkers" and "osteoarthritis". In addition, I have selected some works presented during the 2011 OARSI Congress. This year was dominated by the publication of a consensus paper on the qualification of osteoarthritis (OA) biomarkers by the OARSI/Food Drug Administration (FDA) Osteoarthritis Biomarkers Working Group, and of proteomes of chondrocyte vesicles, urine and serum.

Disciplines :

Rheumatology

Author, co-author :

Henrotin, Yves ; Université de Liège - ULiège > Département des sciences de la motricité > Unité de recherche sur l'os et le cartillage (U.R.O.C.)

Language :

English

Title :

Osteoarthritis year 2011 in review: biochemical markers of osteoarthritis: an overview of research and initiatives.

Publication date :

2012

Journal title :

Osteoarthritis and Cartilage

ISSN :

1063-4584

eISSN :

1522-9653

Publisher :

Elsevier, United Kingdom

Volume :

Issue :

Pages :

215-7

Peer reviewed :

Peer Reviewed verified by ORBi

Commentary :

Available on ORBi :

since 25 June 2012

Statistics

Number of views

64 (7 by ULiège)

Number of downloads

3 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Kraus V., Burnette B., Coindreau J., Cottrell S., Eyre D., Gendreau M., et al. OARSI/FDA Osteoarthritis Biomarkers Working group. Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthritis Cart 2011, 19:515-542.
De Seny D., Sharif M., Fillet M., Cobraiville G., Meuwis M.-A., marée R., et al. Discovery and biochemical characterisation of four novel biomarkers for osteoarthritis. Ann Rheum Dis 2011, 70:1144-1152.
Henrotin Y., Gharbi M., Deberg M., Dubuc J.E., De Pauw E. Fibulin-3 fragments (Fib3-1 and Fib3-2) are potential new biomarkers for the diagnosis of osteoarthritis. Osteoarthritis Cart 2011, 19(Suppl 1):S79.
Albig A.R., Neil J.R., Schiemann W.P. Fibulins 3 and 5 antagonize tumor angiogenesis in vivo. Cancer Res 2006, 66:2621-2629.
Ehlermann J., Weber S., Pfisterer P., Schorle H. Cloning, expression and characterization of the murine Efemp1, a gene mutated in Doyne-Honeycomb retinal dystrophy. Gene Expr Patterns 2003, 3:441-447.
Klenotic P.A., Munier F.L., Marmorstein L.Y., Anand-Apte B. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a binding partner of epithelial growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1). Implications for macular degenerations. J Biol Chem 2004, 279:30469-30473.
Sahebjam S., Khokha R., Mort J.S. Increased collagen and aggrecan degradation with age in the joints of Timp3(-/-) mice. Arthritis Rheum 2007, 56:905-909.
Kevorkian L., Young D.A., Darrah C., Donell S.T., Shepstone L., Porter S., et al. Expression profiling of metalloproteinases and their inhibitors in cartilage. Arthritis Rheum 2004, 50:131-141.
Wakabayashi T., Matsumine A., Nakazora S., Hasegawa M., Iino T., Ota H., et al. Fibulin-3 negatively regulates chondrocyte differentiation. Biochem Biophys Res Commun 2010, 391:1116-1121.
Rosenthal A.K., Gohr C.M., Nimomiya J., Wakim T. Proteomic analysis of articular cartilage vesicles from normal and osteoarthritis cartilage. Arthritis Rheum 2011, 63:401-411.
Bay-Jensen A.C., Liu Q.J., Byrjalsen I., Li Y., Wang J., Pedersen C., Leeming D.J., et al. Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM - Increased serum CIIM in subjects with severe radiographic osteoarthritis. Clin Biochem 2011, 44:423-429.
Catterall J., Hsueh M.-F., Stabler T.V., Renner J.M., Jordan J.M., Kraus V.B. A unique deamidated cartilage oligomeric matrix protein (COMP) biomarker preferentially identifies hip osteoarthritis. Osteoarthritis Cart 2011, 19(Suppl 1). S72(142).
Richette P., Poitou C., Garnero P., Vicaut E., Bouillot J.L., Lacorte J.M., et al. Benefit of massive loss on symptoms, systematic inflammation and cartilage turnover in obese patients with knee osteoarthritis. Ann Rheum Dis 2011, 70:139-144.
Denoble A., Huffman K., Stabler T., Kelley S.J., Hershfield M.S., Mcdaniel G., et al. Uric acid is a danger signal of increasing risk for osteoarthritis through inflammasome activation. Proc Natl Acad Sci USA 2011, 108:2088-2093.
Golightly Y.M., Marshall S.W., Kraus V.B., Renner J.B., Villaveces A., Casteel C., et al. Biomarkers of incident radiographic knee osteoarthritis. Arthritis Rheum 2011, 63:2276-2283.
Eckstein F., Hellio Le Graverand M.P., Charles H.C., Hunter D.J., Kraus V.B., Sunyer T., et al. Clinical, radiographic, molecular and MRI-based predictors of cartilage loss in knee osteoarthritis. Ann Rheum Dis 2011, 70:1223-1230.
Berry P.A., Maclewicz R.A., Wluka A.E., Downey-Jones M.D., Forbes A., Hellawell C.J., et al. Relationship of serum markers of cartilage metabolism to imaging and clinical outcome measures of knee joint structure. Ann Rheum Dis 2010, 69:1816-1822.
Pelletier J.P., Raynauld J.P., Caron J., Mineau F., Abram F., Dorais M., et al. Decrease in serum level of matrix metalloproteinases is predictive of the disease-modifying effect of osteoarthritis drugs assessed by quantitative MRI in patients with knee osteoarthritis. Ann Rheum Dis 2010, 69:2095-2101.